Plain-English translation of NCT07201922 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication called can help slow down early lung changes in people who have a family history of pulmonary fibrosis (a condition where lung tissue becomes scarred). You would take the medication twice daily as a tablet for about 2 to 3 years. The study will compare your lung function and scans over time to see if this treatment helps protect your lungs.
People with a family member who has pulmonary fibrosis are at higher risk of developing the disease themselves. Early detection of lung changes is important, and this trial is exploring whether this medication can prevent those early changes from progressing into serious lung scarring.
You likely qualify if…
You likely don't qualify if…
You would visit the study site frequently for the first 2 years — about every 3 months — and then every 6 months in the third year. At these visits, doctors will test your lung function and take chest scans to monitor your lungs. You'll also receive phone calls from the study team every 3 months during the third year. You'll take a tablet twice daily for about 2 to 3 years; there is a 60% chance you'll receive the medication and a 40% chance you'll receive a placebo (inactive tablet).
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States